Empagliflozin is approved by FDA for the treatment of T2DM in patient with normal renal function, absence of urinary tract infection, and normal body mass index.10It also has highest SGLT2 selectivity when compared to canagliflozin and dapagliflozin.11Empagliflozin acts by increasing renal excretion of glucose, improving the beta cell function, and increasing utilization of lipids over glucose.8 This evidence concerns the gene SLC5A2 and urinary tract infection.